- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02152774
A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma (ROCK - CACG)
April 23, 2015 updated by: Jessica Jasien, New York Glaucoma Research Institute
A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma
To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with chronic angle-closure glaucoma treated for 6 months.
Secondary Outcome
Secondary objectives are:
- To evaluate the early effect of Rho kinase Inhibitor (AR-12286) in reducing intraocular pressure (IOP).
- To evaluate the long term effect of the drug on IOP.
- To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- Glaucoma Associates of New York
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients between 50 and 85 years old; of either sex.
- Patients with CACG with ≥180⁰ PAS
- IOP ≥22 mmHg prior to initiation of treatment in one or both eyes with two measurements taken two hours apart
- No previous intraocular surgery except clear cornea phacoemulsification.
- Corrected visual acuity in both eyes ≥20/50 in the eligible eye
- Not more than 6 diopters spherical equivalent on the study eye
- Not more than 3 diopters cylinder equivalent on the study eye
- Have given written informed consent, prior to any investigational procedures.
- Ability to attend for the 6-month duration of the study
Exclusion Criteria:
- Open angle glaucoma
- Closed angle glaucoma with <180⁰ PAS
- Intraocular pressure >35 mmHg
- Severe glaucomatous damage
- Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
- Previous intraocular surgery except clear cornea phacoemulsification.
- Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study.
- Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or drops for treatment of dry eye syndrome (which may be used throughout the study).
- Any abnormality preventing reliable applanation tonometry of either eye.
- Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
- Changes of systemic medication that could have a substantial effect on IOP anticipated during the study.
- Participation in any investigational study within the past 30 days.
- Inability to perform reliable VF testing.
- Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary.
- Self-reported poor compliance to treatment.
- Reluctance to return for scheduled follow-up visits.
- Patients not able to understand the nature of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.5% Rho-Kinase Inhibitor
AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ.
It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays.
Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma.
It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects.
It is currently in phase II testing.
|
|
Experimental: 0.7% Rho-Kinase Inhibitor
AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ.
It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays.
Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma.
It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects.
It is currently in phase II testing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Long Lasting effect of study drug to reduce IOP
Time Frame: 6 Months
|
To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with CACG treated for 6 months.
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Outcome
Time Frame: 6 Months
|
To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.
|
6 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
February 1, 2015
Study Registration Dates
First Submitted
May 23, 2014
First Submitted That Met QC Criteria
May 28, 2014
First Posted (Estimate)
June 2, 2014
Study Record Updates
Last Update Posted (Estimate)
April 24, 2015
Last Update Submitted That Met QC Criteria
April 23, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14.12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Angle-closure Glaucoma
-
National University Hospital, SingaporeCompletedChronic Angle Closure Glaucoma | Primary Angle Closure | Primary Angle Closure Suspect | Fellow Eyes of Acute Angle Closure GlaucomaSingapore
-
Assaf-Harofeh Medical CenterUnknown
-
University of California, Los AngelesNational Eye Institute (NEI)Active, not recruitingPrimary Open Angle Glaucoma | Chronic Angle Closure Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Khoo Teck Puat HospitalCompletedPrimary Angle-Closure Glaucoma | Primary Angle Closure Without Glaucoma DamageSingapore
-
Chunyan Qiao_2021RecruitingAngle-Closure GlaucomaChina
-
Guangfu DangCompletedPrimary Angle Closure GlaucomaChina
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruitingPrimary Angle-Closure Glaucoma
-
Alcon ResearchCompletedAngle-closure GlaucomaUnited States
-
AllerganCompletedGlaucoma | Angle-ClosureAustralia, Canada, Korea, Republic of, Singapore, Taiwan, United Kingdom
Clinical Trials on Rho-Kinase Inhibitor
-
New York Glaucoma Research InstituteUnknown
-
Robert Ritch, MD, LLC.CompletedOcular Hypertension | Open Angle Glaucoma | Exfoliation SyndromeUnited States
-
New York Glaucoma Research InstituteUnknown
-
Groupe Hospitalier Pitie-SalpetriereVanderbilt University Medical CenterCompleted
-
Fred Hutchinson Cancer CenterSanofiRecruitingChronic Graft Versus Host DiseaseUnited States
-
NCIC Clinical Trials GroupAstex Pharmaceuticals, Inc.CompletedUnspecified Adult Solid Tumor, Protocol Specific | Non-Hodgkins LymphomaCanada
-
Cyclacel Pharmaceuticals, Inc.Terminated
-
LaNova Medicines LimitedTerminatedAdvanced TumoursChina
-
EMD SeronoTerminatedHaematological MalignanciesItaly, United States, Switzerland, Belgium, Germany